Platform Technology

Curewize develops lab tests for improving cancer patients’ survival and quality of life. Our proprietary platform technology measures microRNA (miRNA) profiles in patients’ biofluids. MiRNAs control gene activity, and are considered superior biomarkers for personalized treatment decisions due to their direct link to cancer mechanisms and stability in human biofluid samples. Curewize gains value from clinically validated and commercially adapted miRNA assay technology, and management experienced in developing and commercializing lab tests for prognosis and diagnosis.

Proprietary Platform for Measuring miRNA in Biofluids

Commercializing miRNA Lab Tests